Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course

被引:16
作者
Kim, Kyoungmi [1 ]
Trott, Josephine F. [2 ]
Gao, Guimin [4 ]
Chapman, Arlene [5 ]
Weiss, Robert H. [2 ,3 ,6 ]
机构
[1] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA
[2] Univ Calif Davis, Dept Internal Med, Div Nephrol, Genome & Biomed Sci Bldg,Room 6311, Davis, CA 95616 USA
[3] Univ Calif Davis, Canc Ctr, Davis, CA 95616 USA
[4] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA
[5] Univ Chicago, Nephrol Sect, Chicago, IL 60637 USA
[6] VA Northern Calif Hlth Care Syst, Med Serv, Sacramento, CA 95655 USA
关键词
ADPKD; Metabolomics; Progression; HALT study; DOMINANT POLYCYSTIC KIDNEY; STAGE RENAL-DISEASE; PROGRESSION; METABOLOMICS; MODEL; GROWTH; SERUM; RISK; ACID; PKD1;
D O I
10.1186/s12882-019-1249-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundAutosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is characterized by gradual cyst growth and expansion, increase in kidney volume with an ultimate decline in kidney function leading to end stage renal disease (ESRD). Given the decades long period of stable kidney function while cyst growth occurs, it is important to identify those patients who will progress to ESRD. Recent data from our and other laboratories have demonstrated that metabolic reprogramming may play a key role in cystic epithelial proliferation resulting in cyst growth in ADPKD. Height corrected total kidney volume (ht-TKV) accurately reflects cyst burden and predicts future loss of kidney function. We hypothesize that specific plasma metabolites will correlate with eGFR and ht-TKV early in ADPKD, both predictors of disease progression, potentially indicative of early physiologic derangements of renal disease severity.MethodsTo investigate the predictive role of plasma metabolites on eGFR and/or ht-TKV, we used a non-targeted GC-TOF/MS-based metabolomics approach on hypertensive ADPKD patients in the early course of their disease. Patient data was obtained from the HALT-A randomized clinical trial at baseline including estimated glomerular filtration rate (eGFR) and measured ht-TKV. To identify individual metabolites whose intensities are significantly correlated with eGFR and ht-TKV, association analyses were performed using linear regression with each metabolite signal level as the primary predictor variable and baseline eGFR and ht-TKV as the continuous outcomes of interest, while adjusting for covariates. Significance was determined by Storey's false discovery rate (FDR) q-values to correct for multiple testing.ResultsTwelve metabolites significantly correlated with eGFR and two triglycerides significantly correlated with baseline ht-TKV at FDR q-value <0.05. Specific significant metabolites, including pseudo-uridine, indole-3-lactate, uric acid, isothreonic acid, and creatinine, have been previously shown to accumulate in plasma and/or urine in both diabetic and cystic renal diseases with advanced renal insufficiency.ConclusionsThis study identifies metabolic derangements in early ADPKD which may be prognostic for ADPKD disease progression.Clinical trialHALT Progression of Polycystic Kidney Disease (HALT PKD) Study A; Clinical www.clinicaltrials.gov identifier: NCT00283686; first posted January 30, 2006, last update posted March 19, 2015.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Loss of polycystin-1 or polycystin-2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone receptors
    Allen, E
    Piontek, KB
    Garrett-Mayer, E
    Garcia-Gonzalez, M
    Gorelick, KL
    Germino, GG
    [J]. HUMAN MOLECULAR GENETICS, 2006, 15 (01) : 11 - 21
  • [2] Lipoprotein metabolism and CKD: overview
    Barter, Philip
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (02) : 243 - 246
  • [3] Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells
    Boletta, A
    Qian, F
    Onuchic, LF
    Bhunia, AK
    Phakdeekitcharoen, B
    Hanaoka, K
    Guggino, W
    Monaco, L
    Germino, GG
    [J]. MOLECULAR CELL, 2000, 6 (05) : 1267 - 1273
  • [4] ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing
    Braun, William E.
    Abebe, Kaleab Z.
    Brosnahan, Godela
    Patterson, Charity G.
    Chapman, Arlene B.
    Harris, Peter C.
    Hogan, Marie C.
    Perrone, Ronald D.
    Torres, Vicente E.
    Miskulin, Dana C.
    Steinman, Theodore I.
    Winklhofer, Franz T.
    Rahbari-Oskoui, Frederic F.
    Czarnecki, Peter G.
    Bae, Kyongtae T.
    Grantham, Jared J.
    Flessner, Michael F.
    Schrier, Robert W.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2018, 71 (02) : 294 - 296
  • [5] Validating Quantitative Untargeted Lipidomics Across Nine Liquid Chromatography-High-Resolution Mass Spectrometry Platforms
    Cajka, Tomas
    Smilowitz, Jennifer T.
    Fiehn, Oliver
    [J]. ANALYTICAL CHEMISTRY, 2017, 89 (22) : 12360 - 12368
  • [6] CHAPMAN AB, 1994, J AM SOC NEPHROL, V5, P1349
  • [7] Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016
    Chebib, Fouad T.
    Torres, Vicente E.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 67 (05) : 792 - 810
  • [8] 2-Deoxy-D-Glucose Ameliorates PKD Progression
    Chiaravalli, Marco
    Rowe, Isaline
    Mannella, Valeria
    Quilici, Giacomo
    Canu, Tamara
    Bianchi, Veronica
    Gurgone, Antonia
    Antunes, Sofia
    D'Adamo, Patrizia
    Esposito, Antonio
    Musco, Giovanna
    Boletta, Alessandra
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (07): : 1958 - 1969
  • [9] Fiehn O, 2016, CURRENT PROTOCOLS MO, V114
  • [10] Lkb1 deficiency confers glutamine dependency in polycystic kidney disease
    Flowers, Ebony M.
    Sudderth, Jessica
    Zacharias, Lauren
    Mernaugh, Glenda
    Zent, Roy
    DeBerardinis, Ralph J.
    Carroll, Thomas J.
    [J]. NATURE COMMUNICATIONS, 2018, 9